Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
Virax Biolabs (NASDAQ:VRAX), a biotechnology company specializing in viral disease diagnostics, has appointed Dr. Iain Miller as an Independent Director effective July 29, 2025. Dr. Miller, who replaces outgoing director Yair Erez, brings over 30 years of leadership experience in diagnostics and MedTech sectors.
Dr. Miller's extensive background includes senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has founded four MedTech companies and served as CEO of Presymptom Health, where he developed InfectiClear®. His expertise spans commercial, technical, and regulatory domains, with experience serving on the UK's NICE Technology Appraisal Committee and contributing to NHS England and MHRA innovation programs.
Virax Biolabs (NASDAQ:VRAX), un'azienda biotecnologica specializzata nella diagnostica delle malattie virali, ha nominato il Dr. Iain Miller come Direttore Indipendente a partire dal 29 luglio 2025. Il Dr. Miller, che sostituisce il direttore uscente Yair Erez, porta con sé oltre 30 anni di esperienza dirigenziale nei settori della diagnostica e delle tecnologie mediche.
Il suo ampio background include ruoli di alto livello presso GE Healthcare, bioMérieux e Massachusetts General Hospital. Ha fondato quattro aziende nel campo delle tecnologie mediche ed è stato CEO di Presymptom Health, dove ha sviluppato InfectiClear®. La sua competenza copre ambiti commerciali, tecnici e regolatori, con esperienza nel comitato di valutazione tecnologica NICE del Regno Unito e contributi ai programmi di innovazione del NHS England e MHRA.
Virax Biolabs (NASDAQ:VRAX), una empresa biotecnológica especializada en diagnósticos de enfermedades virales, ha nombrado a Dr. Iain Miller como Director Independiente a partir del 29 de julio de 2025. El Dr. Miller, que reemplaza al director saliente Yair Erez, aporta más de 30 años de experiencia en liderazgo en los sectores de diagnóstico y tecnología médica.
Su amplia trayectoria incluye cargos senior en GE Healthcare, bioMérieux y Massachusetts General Hospital. Ha fundado cuatro empresas de tecnología médica y fue CEO de Presymptom Health, donde desarrolló InfectiClear®. Su experiencia abarca los ámbitos comercial, técnico y regulatorio, con participación en el Comité de Evaluación Tecnológica NICE del Reino Unido y contribuciones a programas de innovación del NHS England y MHRA.
Virax Biolabs (NASDAQ:VRAX)는 바이러스 질병 진단을 전문으로 하는 생명공학 회사로, 2025년 7월 29일부터 Dr. Iain Miller를 독립 이사로 임명했습니다. Dr. Miller는 퇴임하는 이사 Yair Erez를 대체하며, 진단 및 의료기술 분야에서 30년 이상의 리더십 경험을 보유하고 있습니다.
그의 광범위한 경력에는 GE Healthcare, bioMérieux, Massachusetts General Hospital에서의 고위직 경력이 포함되어 있습니다. 그는 4개의 의료기술 회사를 설립했고, Presymptom Health의 CEO로서 InfectiClear®를 개발했습니다. 그의 전문성은 상업적, 기술적, 규제 분야에 걸쳐 있으며, 영국 NICE 기술평가위원회에서 활동하고 NHS England 및 MHRA 혁신 프로그램에 기여한 경험도 있습니다.
Virax Biolabs (NASDAQ:VRAX), une entreprise de biotechnologie spécialisée dans le diagnostic des maladies virales, a nommé Dr. Iain Miller en tant que Directeur Indépendant à compter du 29 juillet 2025. Le Dr Miller, qui remplace le directeur sortant Yair Erez, apporte plus de 30 ans d'expérience en leadership dans les secteurs du diagnostic et des technologies médicales.
Son parcours étendu comprend des postes de direction chez GE Healthcare, bioMérieux et Massachusetts General Hospital. Il a fondé quatre entreprises de MedTech et a été CEO de Presymptom Health, où il a développé InfectiClear®. Son expertise couvre les domaines commercial, technique et réglementaire, avec une expérience au sein du comité d’évaluation technologique NICE du Royaume-Uni et des contributions aux programmes d’innovation du NHS England et de la MHRA.
Virax Biolabs (NASDAQ:VRAX), ein Biotechnologieunternehmen, das sich auf die Diagnostik viraler Erkrankungen spezialisiert hat, hat Dr. Iain Miller mit Wirkung zum 29. Juli 2025 als unabhängigen Direktor ernannt. Dr. Miller, der den ausscheidenden Direktor Yair Erez ersetzt, bringt über 30 Jahre Führungserfahrung in den Bereichen Diagnostik und Medizintechnik mit.
Sein umfangreicher Hintergrund umfasst leitende Positionen bei GE Healthcare, bioMérieux und Massachusetts General Hospital. Er hat vier MedTech-Unternehmen gegründet und war CEO von Presymptom Health, wo er InfectiClear® entwickelte. Seine Expertise erstreckt sich über kommerzielle, technische und regulatorische Bereiche, mit Erfahrungen im NICE Technology Appraisal Committee des Vereinigten Königreichs sowie Beiträgen zu Innovationsprogrammen des NHS England und der MHRA.
- Appointment of highly qualified director with 30+ years of diagnostics and MedTech experience
- Addition of valuable regulatory expertise through Dr. Miller's experience with NICE, NHS England, and MHRA
- Strategic strengthening of leadership team during company's expansion phase
- Loss of existing board member Yair Erez
Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable service and contributions.
Dr. Miller brings over 30 years of leadership experience across the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has worked extensively across both the
Dr. Miller has also served on the
"We are pleased to welcome Iain Miller, PhD to the Virax Board during this important phase of development," said James Foster, Chief Executive Officer of Virax Biolabs. "His leadership across private and public sector organisations, combined with deep diagnostics expertise and international experience, will be instrumental as we work to advance our immune profiling platform — building on our initial Research-Use-Only (RUO) product rollout and progressing toward IVD development, regulatory engagement, and future market entry."
Dr. Miller commented: "I am excited to join the Board of Virax Biolabs at a time of strategic focus and momentum. The Company's immune profiling platform presents a compelling opportunity to enhance how chronic and post-viral conditions are monitored. I look forward to supporting the team in realising this vision."
About Virax Biolabs Group Limited.
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-appoints-iain-miller-phd-as-independent-director-to-accelerate-commercial-strategy-302515923.html
SOURCE Virax BioLabs Group Limited
FAQ
Who is the new Independent Director of Virax Biolabs (NASDAQ:VRAX)?
What is Dr. Iain Miller's background and experience before joining Virax Biolabs?
How will Dr. Miller's appointment benefit Virax Biolabs' strategy?
Who did Dr. Iain Miller replace on Virax Biolabs' Board of Directors?
What are Dr. Iain Miller's academic qualifications?
